Vimta Labs Limited (VIMTALABS.NS)
INR 1016.0
(2.42%)
INR 1016.0
(2.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 410.09 Million INR | -14.87% |
| 2022 | 481.72 Million INR | 16.55% |
| 2021 | 413.3 Million INR | 93.09% |
| 2020 | 214.05 Million INR | 212.71% |
| 2019 | 68.45 Million INR | -72.96% |
| 2018 | 253.11 Million INR | 54.03% |
| 2017 | 164.33 Million INR | 63.6% |
| 2016 | 100.44 Million INR | 56.12% |
| 2015 | 64.33 Million INR | 27.09% |
| 2014 | 50.62 Million INR | -61.76% |
| 2013 | 132.39 Million INR | 214.22% |
| 2012 | 42.13 Million INR | 127.4% |
| 2011 | -153.76 Million INR | -229.6% |
| 2010 | -46.65 Million INR | -275.47% |
| 2009 | 26.58 Million INR | -34.26% |
| 2008 | 40.44 Million INR | -35.25% |
| 2007 | 62.45 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 122.8 Million INR | -0.57% |
| 2023 Q1 | 121.98 Million INR | -3.82% |
| 2023 Q2 | 63.23 Million INR | -48.16% |
| 2023 Q4 | 123.51 Million INR | 21.9% |
| 2023 Q3 | 101.32 Million INR | 60.24% |
| 2023 FY | 410.09 Million INR | -14.87% |
| 2022 Q3 | 102.41 Million INR | -22.48% |
| 2022 Q4 | 126.83 Million INR | 23.85% |
| 2022 FY | 481.72 Million INR | 16.55% |
| 2022 Q1 | 120.37 Million INR | 1.72% |
| 2022 Q2 | 132.11 Million INR | 9.75% |
| 2021 FY | 413.3 Million INR | 93.09% |
| 2021 Q1 | 80.7 Million INR | 4.24% |
| 2021 Q2 | 97.44 Million INR | 20.74% |
| 2021 Q4 | 118.34 Million INR | 1.3% |
| 2021 Q3 | 116.82 Million INR | 19.89% |
| 2020 Q4 | 77.42 Million INR | -4.05% |
| 2020 Q2 | 75.37 Million INR | 487.91% |
| 2020 Q1 | -19.43 Million INR | -3338.33% |
| 2020 FY | 214.05 Million INR | 212.71% |
| 2020 Q3 | 80.69 Million INR | 7.06% |
| 2019 Q2 | 9.03 Million INR | -22.82% |
| 2019 Q4 | 600 Thousand INR | -98.73% |
| 2019 FY | 68.45 Million INR | -72.96% |
| 2019 Q1 | 11.7 Million INR | -82.71% |
| 2019 Q3 | 47.12 Million INR | 421.82% |
| 2018 Q4 | 67.68 Million INR | 32.26% |
| 2018 FY | 253.11 Million INR | 54.03% |
| 2018 Q3 | 51.17 Million INR | -26.55% |
| 2018 Q2 | 69.67 Million INR | 7.86% |
| 2018 Q1 | 64.59 Million INR | 27.47% |
| 2017 Q1 | 10.62 Million INR | -58.27% |
| 2017 Q4 | 50.67 Million INR | -15.15% |
| 2017 FY | 164.33 Million INR | 63.6% |
| 2017 Q3 | 59.71 Million INR | 37.86% |
| 2017 Q2 | 43.31 Million INR | 307.73% |
| 2016 Q2 | 20.44 Million INR | -24.58% |
| 2016 Q1 | 27.1 Million INR | 49.88% |
| 2016 Q4 | 25.46 Million INR | -11.75% |
| 2016 FY | 100.44 Million INR | 56.12% |
| 2016 Q3 | 28.84 Million INR | 41.11% |
| 2015 FY | 64.33 Million INR | 27.09% |
| 2015 Q4 | 18.08 Million INR | 104.23% |
| 2015 Q2 | 24.75 Million INR | 95.92% |
| 2015 Q3 | 8.85 Million INR | -64.23% |
| 2015 Q1 | 12.63 Million INR | -24.33% |
| 2014 Q3 | 5.38 Million INR | -46.31% |
| 2014 Q4 | 16.7 Million INR | 210.43% |
| 2014 Q2 | 10.02 Million INR | -45.91% |
| 2014 FY | 50.62 Million INR | -61.76% |
| 2014 Q1 | 18.52 Million INR | 1.4% |
| 2013 Q2 | 38.34 Million INR | 2.52% |
| 2013 Q4 | 18.26 Million INR | -52.4% |
| 2013 FY | 132.39 Million INR | 214.22% |
| 2013 Q3 | 38.37 Million INR | 0.06% |
| 2013 Q1 | 37.4 Million INR | 132.1% |
| 2012 Q4 | 16.11 Million INR | 30.47% |
| 2012 FY | 42.13 Million INR | 127.4% |
| 2012 Q1 | 4.8 Million INR | 107.1% |
| 2012 Q3 | 12.35 Million INR | 39.46% |
| 2012 Q2 | 8.85 Million INR | 84.31% |
| 2011 FY | -153.76 Million INR | -229.6% |
| 2011 Q4 | -67.65 Million INR | -79.43% |
| 2011 Q3 | -37.7 Million INR | -10.98% |
| 2011 Q2 | -33.97 Million INR | 0.0% |
| 2010 FY | -46.65 Million INR | -275.47% |
| 2009 FY | 26.58 Million INR | -34.26% |
| 2008 FY | 40.44 Million INR | -35.25% |
| 2007 FY | 62.45 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 568.37 Million INR | 27.848% |
| Dr. Lal PathLabs Limited | 3.57 Billion INR | 88.536% |
| Metropolis Healthcare Limited | 1.27 Billion INR | 67.916% |
| Thyrocare Technologies Limited | 707.6 Million INR | 42.045% |
| Vijaya Diagnostic Centre Limited | 1.18 Billion INR | 65.488% |